Across TCGA pan-cancer cohorts, BORCS6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BORCS6 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher BORCS6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BORCS6 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

COAD, LUAD, and PDAC are the cancer types where BORCS6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.934	1.000	.038	12	view →
LUAD	DFS	Tertile	II,III,IV	0.789	0.964	.008	11	view →
PDAC	OS	Median	IV	0.836	0.491	.024	5	view →
LSCC	DFS	Median	All	0.614	0.867	.039	1	view →
GBM	OS	Tertile	All	0.428	0.608	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BORCS6 tumor-vs-normal RNA expression · all BORCS6 data types